研究单位：[1]Shanghai Zhangjiang Biotechnology Limited Company[2]China-Japan Friendship Hospital[3]Beijing Chaoyang Hospital[4]Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology [5]The First Affiliated Hospital of Guangzhou Medical University
The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.
